RxDoctor Payments Data

Gregorio Ruelas, MD

Family Medicine · Oxnard, CANPI 1447441092

Payments from drug & device makers

$152in general payments, 2019–2025

Across 7 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$31
  • GSK$30
  • Abbott$29
  • AbbVie$27
  • Amgen$18
  • Teva Pharmaceuticals USA, Inc.$17

What the payments were for

  • Food & beverage$152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis2$31
GSK1$30
Abbott1$29
AbbVie1$27
Amgen1$18
Teva Pharmaceuticals USA, Inc.1$17

How this compares

$152 in reported general payments places this provider in the 40th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$127,706
Medicare patients
325
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$168,858
TrulicityDulaglutide64$108,046
EliquisApixaban77$99,238
JardianceEmpagliflozin45$70,682
JanuviaSitagliptin Phosphate27$37,259
XareltoRivaroxaban20$32,539
MounjaroTirzepatide27$26,556
LinzessLinaclotide17$22,612
FarxigaDapagliflozin Propanediol20$13,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,321
RybelsusSemaglutide11$12,038
Tresiba Flextouch U-100Insulin Degludec17$11,774
BrilintaTicagrelor13$7,006
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$5,877
Atorvastatin Calcium623$5,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$27$22,61217 claims
GSKTrelegy Ellipta$30$13,32118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 10,533 family medicine providers in California.

Other family medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →